Özdemir, Ö. Et Al. 2022. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.. Anti-cancer drugs .

Özdemir, Ö., Zengel, B., Yildiz, Y., Oyan Uluç, B., Çabuk, D., Özden, E., ... Kivrak Salim, D.(2022). The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.. Anti-cancer drugs .

Özdemir, Özlem Et Al. "The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.," Anti-cancer drugs , 2022

Özdemir, Özlem Et Al. "The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.." Anti-cancer drugs , 2022

Özdemir, Ö. Et Al. (2022) . "The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.." Anti-cancer drugs .

@article{article, author={Özlem Özdemir Et Al. }, title={The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.}, journal={Anti-cancer drugs}, year=2022}